Eli Lilly

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

News

Lilly says 2026 looks good, as sales rocket in Q4

Eli Lilly is predicting strong sales and profit growth in 2026, seemingly shrugging off the pricing pressure that weighed heavily on Novo Nordisk.

News

Lilly names Pennsylvania site for its latest US facility

Eli Lilly has revealed the fourth new manufacturing site in its $27 billion capital investment spree in the US - a $3.5bn facility in Pennsylvania.

Head-to-head trial dents Novo Nordisk's obesity hopes

Kailera, Hengrui stake claim to oral weight loss category

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

Lilly strikes $8.8bn-plus alliance with China's Innovent

Lilly says 2026 looks good, as sales rocket in Q4

Lilly names Pennsylvania site for its latest US facility

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks